Neurotech stocks analysis: Compumedics, NeuroPace, CVRx, BrainsWay identified as overlooked plays in $38B 2032 market
Summary
A comprehensive neurotech stock analysis highlighted Compumedics (Somfit D disposable launch), NeuroPace (first-ever positive EBITDA + Nautilus next-gen RNS), CVRx (Barostim expanding from heart failure to hypertension), and BrainsWay (adolescent depression clearance + real-world OCD data) as underappreciated neurotech plays in a sector projected to grow from $13B in 2022 to $38B by 2032 at 11.5% CAGR. The analysis framed neurotech as the "shift from chemical pharmacology to bioelectronic medicine" driven by the aging population demographic inevitability.
Why it matters
Mainstream financial analysis identifying neurotech as a structural investment theme driven by demographic inevitability — aging populations and inadequate pharmacological options — legitimizes the sector for generalist investors who have not previously tracked neuromodulation. The $38B 2032 projection from market research firms creates the TAM narrative that growth investors need to allocate capital to the sector.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial